New findings in Alzheimers research

November 16, 2015

Current Alzheimer's research focuses on the amyloid precursor protein (APP), which is responsible for the formation of destructive plaques in the brain. Researchers from Bochum have now demonstrated that APP, in addition to forming those plaques, might also affect the development of Alzheimer's disease via another mechanism.

Protein in the cell membrane

Under certain circumstance, APP causes the formation of spherical structures in the nucleus, so-called spheres. They affect the activity of some genes, which may result in a modulation of neurotransmitter activity. Neurotransmitters are biochemical transmitters that transmit excitation from a nerve cell to other . APP itself is a protein that is anchored in the . In this capacity, it has several binding sites where other proteins can dock, thus triggering a number of different processes. One of the adaptor proteins is FE65. Under certain circumstances, it can enter the cell nucleus with the aid of the APP. There, FE65 together with other proteins forms the spherical structures specified above. It had previously not been understood in what way they affect the cells.

Comparison between different cell cultures

Dr Thorsten Müller from Medizinisches Proteom-Center explains how he and his PhD student Christina Looße have proceeded to gain a better understanding of the spheres' potential influence on the brain: "In our study, we have established a cell culture model inside which we can switch on specific sphere formation. The cells that have been switched on generate spheres." The researchers compared them with cells that were switched off and which did not show any sphere formation. "In the process, we discovered that sphere-forming cells exhibit higher expression of the bestrophin 1-gene," says Müller

Biochemical transmitters and Alzheimer's disease

Bestrophin 1 has recently been described in the context of impaired neurotransmitter activity in Alzheimer's disease. "Elevated levels of the neurotransmitter GABA in the cerebrospinal fluid of Alzheimer's patients have already been described, and our study may shed light on how neurotransmitter modulations correlate with the APP," as Dr Thorsten Mülller elaborates the relevance of his research work for medical science.

Starting point for future therapies

Contrary to previous assumptions, the APP could thus affect the development of Alzheimer's disease, inasmuch as it affects an inhibition of neurotransmitter activity and is not relevant as a precursor of plaques in the first place. "This hypothesis might provide interesting starting points for the development of therapies for the treatment of Alzheimer's disease," says Thorsten Müller.

Explore further: How Alzheimer's could occur: Protein spheres in the nucleus give wrong signal for cell division

More information: Christina Loosse et al. Nuclear spheres modulate the expression of BEST1 and GADD45G, Cellular Signalling (2016). DOI: 10.1016/j.cellsig.2015.10.019

Related Stories

Protein repairs nerve cell damage

November 5, 2015

In laboratory experiments on the basic mechanisms that cause Alzheimer's dementia, an international research team led by Heidelberg neurobiologist Prof. Dr. Ulrike Müller and a team of French scientists have succeeded in ...

Study reveals new link between Down syndrome and Alzheimer's

November 2, 2015

Individuals with Down syndrome who survive into adulthood face the additional challenge of early-onset dementia, in which toxic amyloid plaques build up in the brain. The condition is strikingly similar to Alzheimer's disease, ...

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011

Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Recommended for you

Rate of Alzheimer's deaths on the rise

June 15, 2017

The rate of death from Alzheimer's disease in the United States increased by more than 50 percent in the past 15 years, according to new data from the Centers for Disease Control and Prevention.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

baudrunner
not rated yet Nov 16, 2015
My understanding is that APP starts out as an ordinary peptide which does not pass all the way through the cell membrane because somehow in that hydrophobic layer, through some kind of enzymatic activity, it becomes misfolded and remains there to initiate the process that leads to the aggregation of plaques and tangles. If the APP precursor can be identified, then a targeting enzyme designed to break it up before it begins to permeate the cell membrane may be able to prevent this entire process from the onset. That would constitute a preventive cure.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.